Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre. Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated are acting as the joint book-running managers for the proposed offering. Wedbush Securities Inc. is acting as lead manager for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics announces poster presentations at UEGW 2025
- Spyre Therapeutics initiated with a Buy at Deutsche Bank
- Promising Developments and Strategic Trials Drive Buy Rating for Spyre Therapeutics
- Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial
- Strategic Growth and Innovation Drive Buy Rating for Spyre Therapeutics